Identification of novel glucocerebrosidase chaperones by unexpected skeletal rearrangement reaction

Bioorg Med Chem Lett. 2023 Nov 15:96:129531. doi: 10.1016/j.bmcl.2023.129531. Epub 2023 Oct 20.

Abstract

Compound 5 was identified from a high-throughput screening campaign as a small molecule pharmacological chaperone of glucocerebrocidase (GCase), a lysosomal hydrolase encoded by the GBA1 gene, variants of which are associated with Gaucher disease and Parkinson's disease. Further investigations revealed that compound 5 was slowly transformed into a regio-isomeric compound (6) in PBS buffer, plausibly via a ring-opening at hemiaminal moiety accompanied by subsequent intramolecular CC bond formation. Utilising this unexpected skeletal rearrangement reaction, a series of compound 6 analogues was synthesized which yielded multiple potent GCase pharmacological chaperones with sub-micromolar EC50 values as exemplified by compound 38 (EC50 = 0.14 μM).

Keywords: Gaucher disease; Glucocerebrosidase; Parkinson disease; Pharmacological chaperone; Rearrangement reaction.

MeSH terms

  • Gaucher Disease* / drug therapy
  • Glucosylceramidase / genetics
  • Humans
  • Molecular Chaperones
  • Mutation
  • Parkinson Disease*

Substances

  • Glucosylceramidase
  • Molecular Chaperones